BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

...all who visit the site. Elizabeth S. Eaton, Staff Writer Innovative Medicines Initiative (IMI) Wageningen University and Research Centre University of Tuebingen Leiden...
BioCentury | Jul 19, 2019
Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

...fuses ADAR2 to deactivated Cas13 to convert A to I in RNA. This year, a University of Tuebingen...
BioCentury | Feb 12, 2019
Translation in Brief

Storm’s RNA modification software

...YTH N6-Methyladenosine RNA binding protein 1 Michael Leviten, Senior Writer Accent Therapeutics Inc. Storm Therapeutics Ltd. University of Chicago University of Tuebingen Programmed...
BioCentury | Jan 30, 2019
Distillery Techniques

Biomarkers

...Diseases, Bonn, Germany, and University of Tübingen, Tübingen, Germany email: mathias.jucker@uni-tuebingen.de Chris Lieu German Center for Neurodegenerative Diseases University of Tuebingen Neurofilament...
BioCentury | Mar 7, 2018
Distillery Therapeutics

Neurology

...online Feb. 23, 2018 doi:10.1073/pnas.1716071115 CONTACT: Thorsten Schmidt, University of Tübingen, Tübingen, Germany email: thorsten.schmidt@med.uni-tuebingen.de Hongjiang Li University of Tuebingen Ataxin...
BioCentury | Mar 30, 2017
Emerging Company Profile

Unlocking liver regeneration

...MKK4 as a key regulator of liver regeneration.” Cell (2013) Mark Zipkin, Staff Writer Hannover Medical School HepaRegeniX GmbH University of Tuebingen...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Infectious disease

...online Jan. 23, 2017 doi:10.1038/nmicrobiol.2016.257 CONTACT: Christopher Weidenmaier, University of Tübingen, Tübingen, Germany email: christopher.weidenmaier@med.uni-tuebingen.de Winnie Pong University of Tuebingen S...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...Rudalska, R. et al. Nat. Med.; published online Sept. 14, 2014; doi:10.1038/nm.3679 Contact: Lars Zender, University of Tuebingen...
BioCentury | Jan 30, 2014
Translation in Brief

Translational tidbits

...Euronext:CARD); AdjuCor GmbH; Boston Scientific Corp. (NYSE:BSX); Contipro Biotech s.r.o.; Explora Biotech s.r.l.; Innova S.p.A. Eberhard Karls University...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Inflammation

...et al. J. Med. Chem.; published online Oct. 17, 2013; doi:10.1021/jm401276h Contact: Stefan A. Laufer, Eberhard Karls University...
Items per page:
1 - 10 of 35
BioCentury | Feb 25, 2020
Product Development

Europe ramps up response to COVID-19 outbreak

...all who visit the site. Elizabeth S. Eaton, Staff Writer Innovative Medicines Initiative (IMI) Wageningen University and Research Centre University of Tuebingen Leiden...
BioCentury | Jul 19, 2019
Preclinical News

July 19 Preclinical Quick Takes: Samumed's Alzheimer's candidate; plus a CRISPR RNA editing tool, new targets for fibrosis and pain

...fuses ADAR2 to deactivated Cas13 to convert A to I in RNA. This year, a University of Tuebingen...
BioCentury | Feb 12, 2019
Translation in Brief

Storm’s RNA modification software

...YTH N6-Methyladenosine RNA binding protein 1 Michael Leviten, Senior Writer Accent Therapeutics Inc. Storm Therapeutics Ltd. University of Chicago University of Tuebingen Programmed...
BioCentury | Jan 30, 2019
Distillery Techniques

Biomarkers

...Diseases, Bonn, Germany, and University of Tübingen, Tübingen, Germany email: mathias.jucker@uni-tuebingen.de Chris Lieu German Center for Neurodegenerative Diseases University of Tuebingen Neurofilament...
BioCentury | Mar 7, 2018
Distillery Therapeutics

Neurology

...online Feb. 23, 2018 doi:10.1073/pnas.1716071115 CONTACT: Thorsten Schmidt, University of Tübingen, Tübingen, Germany email: thorsten.schmidt@med.uni-tuebingen.de Hongjiang Li University of Tuebingen Ataxin...
BioCentury | Mar 30, 2017
Emerging Company Profile

Unlocking liver regeneration

...MKK4 as a key regulator of liver regeneration.” Cell (2013) Mark Zipkin, Staff Writer Hannover Medical School HepaRegeniX GmbH University of Tuebingen...
BioCentury | Jan 25, 2017
Distillery Therapeutics

Infectious disease

...online Jan. 23, 2017 doi:10.1038/nmicrobiol.2016.257 CONTACT: Christopher Weidenmaier, University of Tübingen, Tübingen, Germany email: christopher.weidenmaier@med.uni-tuebingen.de Winnie Pong University of Tuebingen S...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...Rudalska, R. et al. Nat. Med.; published online Sept. 14, 2014; doi:10.1038/nm.3679 Contact: Lars Zender, University of Tuebingen...
BioCentury | Jan 30, 2014
Translation in Brief

Translational tidbits

...Euronext:CARD); AdjuCor GmbH; Boston Scientific Corp. (NYSE:BSX); Contipro Biotech s.r.o.; Explora Biotech s.r.l.; Innova S.p.A. Eberhard Karls University...
BioCentury | Nov 21, 2013
Distillery Therapeutics

Indication: Inflammation

...et al. J. Med. Chem.; published online Oct. 17, 2013; doi:10.1021/jm401276h Contact: Stefan A. Laufer, Eberhard Karls University...
Items per page:
1 - 10 of 35